Verastem (NASDAQ:VSTM) Stock Gets Price Target Increase from BTIG Research

Verastem (NASDAQ:VSTM) had its target price hoisted by investment analysts at BTIG Research from $18.00 to $24.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BTIG Research’s price target would suggest a potential upside of 211.28% from the company’s previous close.

VSTM has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Verastem in a report on Monday, October 5th. Jefferies Financial Group restated a “buy” rating and set a $13.00 target price on shares of Verastem in a research note on Wednesday. Citigroup reaffirmed a “buy” rating on shares of Verastem in a research report on Thursday, October 8th. Wolfe Research began coverage on Verastem in a research note on Thursday, September 17th. They issued an “outperform” rating for the company. Finally, Weiss Ratings raised Verastem from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 4th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Verastem Trading Up 3.5%

NASDAQ VSTM opened at $7.71 on Thursday. Verastem has a 52 week low of $3.43 and a 52 week high of $10.82. The company has a 50 day moving average price of $7.54 and a 200 day moving average price of $5.91. The company has a quick ratio of 2.22, a current ratio of 2.25 and a debt-to-equity ratio of 1.48. The firm has a market cap of $698.22 million, a PE ratio of -2.90 and a beta of 0.39.

Verastem (NASDAQ:VSTM) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.08. Verastem had a negative net margin of 231.59% and a negative return on equity of 467.49%. The company had revenue of $40.08 million during the quarter, compared to the consensus estimate of $22.88 million. As a group, sell-side analysts forecast that Verastem will post -1.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other Verastem news, CEO Dan Paterson sold 44,121 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $8.00, for a total transaction of $352,968.00. Following the sale, the chief executive officer owned 652,712 shares in the company, valued at approximately $5,221,696. The trade was a 6.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 48,044 shares of company stock worth $381,484. 1.94% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Verastem

Large investors have recently bought and sold shares of the company. Royal Bank of Canada boosted its holdings in shares of Verastem by 15.3% in the 1st quarter. Royal Bank of Canada now owns 110,729 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 14,683 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Verastem in the fourth quarter worth $117,000. Bank of New York Mellon Corp raised its holdings in shares of Verastem by 31.8% during the first quarter. Bank of New York Mellon Corp now owns 161,707 shares of the biopharmaceutical company’s stock worth $857,000 after purchasing an additional 39,018 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of Verastem during the first quarter worth $210,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Verastem during the first quarter worth $377,000. Hedge funds and other institutional investors own 88.37% of the company’s stock.

Verastem News Roundup

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: Promising cancer-treatment data: VS-7375 demonstrated anti-tumor activity in advanced KRAS G12D-mutated pancreatic, lung and colorectal cancers. The company reported a 50% confirmed objective response rate in second-line pancreatic ductal adenocarcinoma, including two complete responses in second-line-or-later disease, with favorable safety and tolerability. VS-7375 clinical data
• Positive Sentiment: Path toward Phase III: The results strengthen the investment case for VS-7375 and support Verastem’s preparation for pivotal, late-stage testing. Positive results in multiple tumor types could expand the drug’s commercial opportunity if confirmed in larger trials. Verastem Phase III plans
• Positive Sentiment: Substantial funding secured: Verastem priced an underwritten offering expected to raise approximately $250 million, consisting of 30.94 million common shares at $8.00 each and pre-funded warrants. The proceeds should provide important capital for clinical development and reduce near-term financing risk. Verastem offering
• Positive Sentiment: Leadership succession announced: Michael P. Bailey will become president and CEO on January 1, 2027, when Daniel Paterson retires. The planned transition may provide continuity while the company advances VS-7375 into later-stage development. CEO succession announcement
• Neutral Sentiment: Trading in VSTM was briefly halted under a limit-up/limit-down pause, reflecting unusually active trading and volatility surrounding the announcements.
• Negative Sentiment: The equity financing will materially increase the share count, creating dilution for existing holders. Investors must also weigh the risks that early clinical results may not be replicated in Phase III trials or lead to regulatory approval.

About Verastem

Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research is aimed at addressing cancers with limited treatment options, including ovarian cancer and other solid tumors.

Verastem’s lead product, avutometinib, is a treatment targeting the RAF/MEK signaling pathway and is marketed in the United States under the brand name Avmapki for certain patients with recurrent low-grade serous ovarian cancer.